SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV)
SKBI
SKBI was delisted on the 18th of December, 2015.
10 hedge funds and large institutions have $426K invested in SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) in 2015 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 7 closing their positions.
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
33% less funds holding
Funds holding: 15 → 10 (-5)
69% less capital invested
Capital invested by funds: $1.4M → $426K (-$970K)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$29.3K |
| 2 |
Renaissance Technologies
New York
|
+$15.9K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
+$4.81K |
| 4 |
Morgan Stanley
New York
|
+$3.96K |
| 5 |
Walleye Trading
New York
|
+$321 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$81K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$65K |
| 3 |
CAM
ClariVest Asset Management
San Diego,
California
|
-$53K |
| 4 |
SIM
Spark Investment Management
New York
|
-$39K |
| 5 |
EGA
Eagle Global Advisors
Houston,
Texas
|
-$30K |
SKBI Hedge Fund Activity: Q3 2015 in Review
10 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) (SKBI) for Q3 2015, worth a combined $426K — down 69% from $1.4M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of SKBI and 2 opened new positions — a net loss of 5 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $29.3K. The largest seller was Royal Bank of Canada, exiting entirely with an estimated $81K sold.
- 10 institutional investors held SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) (SKBI) as of Q3 2015, down from 15 in Q2 2015.
- Funds reported $426K of SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) stock for Q3 2015, down 69% quarter-over-quarter.
- 2 funds opened new SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) positions in Q3 2015 and 7 closed out, a net change of -5 holders.
- The largest SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) buyer in Q3 2015 was Citadel Advisors, an estimated $29.3K added.
- The largest SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) seller in Q3 2015 was Royal Bank of Canada, an estimated $81K sold.
Based on aggregated 13F filings for Q3 2015.